Halozyme Therapeutics Inc (HALO)
45.70
-0.06
(-0.13%)
USD |
NASDAQ |
Nov 21, 16:00
45.70
0.00 (0.00%)
After-Hours: 04:47
Halozyme Therapeutics Enterprise Value: 6.652B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 6.652B |
| November 20, 2024 | 6.660B |
| November 19, 2024 | 6.539B |
| November 18, 2024 | 6.254B |
| November 15, 2024 | 6.646B |
| November 14, 2024 | 7.703B |
| November 13, 2024 | 8.295B |
| November 12, 2024 | 8.422B |
| November 11, 2024 | 8.610B |
| November 08, 2024 | 8.596B |
| November 07, 2024 | 8.427B |
| November 06, 2024 | 8.552B |
| November 05, 2024 | 8.309B |
| November 04, 2024 | 8.277B |
| November 01, 2024 | 8.109B |
| October 31, 2024 | 7.272B |
| October 30, 2024 | 7.274B |
| October 29, 2024 | 7.281B |
| October 28, 2024 | 7.258B |
| October 25, 2024 | 7.104B |
| October 24, 2024 | 7.110B |
| October 23, 2024 | 7.299B |
| October 22, 2024 | 7.394B |
| October 21, 2024 | 7.422B |
| October 18, 2024 | 7.529B |
| Date | Value |
|---|---|
| October 17, 2024 | 7.487B |
| October 16, 2024 | 7.637B |
| October 15, 2024 | 7.683B |
| October 14, 2024 | 7.699B |
| October 11, 2024 | 7.579B |
| October 10, 2024 | 7.468B |
| October 09, 2024 | 7.281B |
| October 08, 2024 | 7.722B |
| October 07, 2024 | 7.687B |
| October 04, 2024 | 8.365B |
| October 03, 2024 | 8.524B |
| October 02, 2024 | 8.235B |
| October 01, 2024 | 8.041B |
| September 30, 2024 | 8.118B |
| September 27, 2024 | 8.190B |
| September 26, 2024 | 8.188B |
| September 25, 2024 | 8.051B |
| September 24, 2024 | 8.093B |
| September 23, 2024 | 8.388B |
| September 20, 2024 | 8.478B |
| September 19, 2024 | 8.511B |
| September 18, 2024 | 8.867B |
| September 17, 2024 | 8.819B |
| September 16, 2024 | 8.943B |
| September 13, 2024 | 8.866B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.900B
Minimum
Mar 18 2020
9.276B
Maximum
Dec 02 2022
5.857B
Average
6.003B
Median
Apr 12 2023
Enterprise Value Benchmarks
| Abbott Laboratories | 210.81B |
| Novavax Inc | 547.62M |
| Insulet Corp | 18.87B |
| BioLife Solutions Inc | 1.164B |
| TransMedics Group Inc | 2.841B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 137.01M |
| Revenue (Quarterly) | 290.08M |
| Total Expenses (Quarterly) | 126.89M |
| EPS Diluted (Quarterly) | 1.05 |
| Gross Profit Margin (Quarterly) | 82.96% |
| Profit Margin (Quarterly) | 47.23% |
| Earnings Yield | 6.61% |
| Operating Earnings Yield | 8.04% |
| Normalized Earnings Yield | 6.307 |